Back to Search
MARK KIERAN, MD PHD
MD PHD
Pediatric Hematology & Oncology Physician
NPI: 1790747236Individual
Specialties, Licenses & Credentials
Pediatrics — Pediatric Hematology-Oncology
Code: 2080P0207X
76146(MA)
Research & Publications (20)
Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
PMID 19065567·Pediatr Blood Cancer·2009
3-trial
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
PMID 17634493·J Clin Oncol·2007
3-trial
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer.
PMID 16282886·J Pediatr Hematol Oncol·2005
3-trial
Anti-angiogenic chemotherapy in central nervous system tumors.
PMID 15015568·Cancer Treat Res·2004
6-review
Antiangiogenesis therapy. Current and future agents.
PMID 11765376·Hematol Oncol Clin North Am·2001
6-review
A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors.
PMID 19422022·Pediatr Blood Cancer·2009
8-other
Small molecule inhibitors in children with malignant gliomas.
PMID 19434732·Pediatr Blood Cancer·2009
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 BINNEY ST, ROOM SW331
BOSTON, MA 02115 - Phone
- (617) 632-4907
Quick Facts
- NPI
- 1790747236
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile